Status:
COMPLETED
COPD Originates in Polluted Air
Lead Sponsor:
University of British Columbia
Conditions:
COPD
Eligibility:
All Genders
40-75 years
Phase:
NA
Brief Summary
The investigators are investigating the effects of traffic-related diesel exhaust on lung function and the immune system in those at risk for COPD. The individual will be exposed to either filtered ai...
Detailed Description
1. Purpose: To study the effects of traffic related diesel exhaust on people at risk for developing COPD. 2. Hypotheses: Hypothesis 1: An increase in proteins, in the exposed lung and blood, t...
Eligibility Criteria
Inclusion
- Age between 40-75 years of age
- Free of cardiovascular disease
- Free of insulin-dependent diabetes
- Study participants must agree to adhere to the following medication intake protocol 24 hours prior to study visits:
- participants will be asked to withhold:
- short-acting beta2-agonists (SABAs) for 4 hours prior to testing
- long-acting beta2-agonists (LABAs) for 12 hours prior to testing if taken in an individual inhaler (different inhaler from inhaled corticosteroid inhaler)
- LABAs and ICS for 24hrs, if those two medication groups are combined in one inhaler
- ICS (if taken alone as a mono-therapy, or if taken with either a LABA or SABA, but in two separate inhaler), for 24 hrs.
- Overall, we are looking for 15 healthy controls without a history of smoking; 20 individuals with a history of smoking, but who have been non-smokers for at least 6 months prior to study participation; and 15 mild-moderate COPD patients (GOLD I and GOLD II).
Exclusion
- Not between the ages of 40-65 years.
- Are pregnant, breast-feeding, or planning to get pregnant in the following 12 months.
- Are currently using inhaled corticosteroids.
- Are allergic to salbutamol, lidocaine, fentanyl or midazolam.
- Are currently participating in another study that involves taking medications.
- Have unstable COPD symptoms.
- Have clinically significant comorbidities (i.e., coronary artery disease).
- Have a history/clinical evidence of asthma.
- Have contraindications to exercise testing.
- Have a body mass index \<18.5.
- Regularly use of antihistamines, non-steroidal anti-inflammatories, anticoagulants, acetylsalicylic acid (ASA) or decongestants.
Key Trial Info
Start Date :
October 27 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2019
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT02236039
Start Date
October 27 2014
End Date
May 1 2019
Last Update
November 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia
Vancouver, British Columbia, Canada, V5Z 1M9